References
- Gralnick H R, Henderson E. Hypofibrinoginemia and coagulation factor deficiencies with L-asparaginase treatment. Cancer 1971; 27: 1313–20
- Mitchell L, Hoogendoorn H, Giles A R, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukaemia: Risk of thrombotic complications in L-asparaginase-induced anti-thrombin III deficiency. Blood 1994; 83(2)386–91
- Castaman G, Rodeghiero F, Dini E. Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukaemia. Haematologica 1990; 75(6)567–9
- Gugliotta L, Mazzucconi M G, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, Tura S, Mandelli F, GIMEMA Group. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy. A retrospective study. The GIMEMA Group. Eur J Haem 1992; 49(2)63–6
- Feinberg W M, Swenson M R. Cerebrovascular complications of L-asparaginase therapy. Neurology 1988; 38: 127–133
- Ott N, Ramsay N, John R, Priest J, Lipton M, Pui C, Steinherz P, Nesbit M. Sequelae of thrombotic or haemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukaemia. Am J Ped Hem Onco 1988; 10(3)191–5
- Mattiolli-Belmonte M, Gugliotta L, Delvos U, Catani L, Vianelli N, Cascione M L, Bilardinelli A R, Mottola L, Tura S. A regimen for anti-thrombin III substitution in patients with acute lymphoblastic leukaemia under treatment with L-asparaginase. Haematologica 1991; 76(3)209–14
- Nowak-Gotti U, Binder M, Hassel J U, Wolf J, Huseman S, Ritter J. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase induced coagulation factor deficiencies during ALL induction therapy. Haematologica 1996; 81(2)191
- Carlsson H, Stockelberg D, Tengborn L, Braide I, Carneskog J, Kutti J. Effects of Erwinia-asparaginase on the coagulation system. Eur J Haematol 1995; 55(5)289–93
- Pogliani E M, Parma M, Baragetti I, Musarda G, Rivolta F, Maffe P, Corneo G. L-asparaginase in acute lymphoblastic leukaemia treatment: The role of antithrombin III concentrates in regulating the prothrombotic state induced by therapy. Acta Haematol 1995; 93(1)5–8
- Nowak-Gotti U, Wermes C, Junker R, Koch H G, Schobess R, Fleischhack G, Schwabe D, Ehrenforth S. A prospective evaluation of thrombotic risk in children with acute lymphoblastic leukaemia carrying the TT677 genotype, the prothrombin G20210A variant and further prothrombotic risk factors. Blood 1999; 93(5)1595–99